ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Report) received a Buy rating and price target from ...

In a report released on January 31, Davinthra Thillainathan from Goldman Sachs maintained a Buy rating on Resmed Inc CHESS Depositary Interests ...

Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...

An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) is now available. ResMed Inc has ...

ResMed's 10.2% revenue jump in Q2 was driven by strong demand for sleep health products, with a particular focus on expansion in digital health platforms. The 29.3% year-over-year bump up in ...

The company's revenue for the period rose 10.3% to $1.282 billion from $1.162 billion last year. Resmed Inc earnings at a glance (GAAP) : -Earnings: $344.6 Mln. vs. $208.6 Mln. last year.

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD) shares are popular blue chip options for investors. But are they in the buy zone right now? Let's take a look at what one leading broker is saying ...

What is the current share price of ResMed Inc. (RMD)? ResMed Inc.'s (RMD) current share price is $37.69. This constitutes a price movement of 6.20% when compared to the share price 7 days ago and is ...

ResMed continues to expand its penetration within the U.S., where market penetration exceeds 10 per cent, while international markets remain under 10 per cent, presenting significant room for growth.